Last reviewed · How we verify
AT7519M
AT7519M is a potent inhibitor of the JAK2 protein.
AT7519M is a potent inhibitor of the JAK2 protein. Used for Myeloproliferative neoplasms.
At a glance
| Generic name | AT7519M |
|---|---|
| Sponsor | Astex Pharmaceuticals, Inc. |
| Drug class | JAK2 inhibitor |
| Target | JAK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting JAK2, AT7519M reduces the activity of the JAK2 protein, which is involved in the signaling of various cytokines and growth factors. This can lead to the inhibition of tumor growth and proliferation.
Approved indications
- Myeloproliferative neoplasms
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma (PHASE1, PHASE2)
- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (PHASE2)
- AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma (PHASE1)
- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT7519M CI brief — competitive landscape report
- AT7519M updates RSS · CI watch RSS
- Astex Pharmaceuticals, Inc. portfolio CI